Beijing, China

Can Liu

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 6.9

ph-index = 1


Company Filing History:


Years Active: 2019-2020

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Can Liu - Innovator in Chemical and Pharmaceutical Technology

Introduction

Can Liu is a prominent inventor based in Beijing, China. He has made significant contributions to the field of chemical and pharmaceutical technology. With a focus on developing innovative solutions for medical applications, Liu has been awarded a total of 2 patents.

Latest Patents

Liu's latest patents include a STAT3 and ERK signal pathway inhibitor comprising mogrosides and analogs thereof. This invention relates to a chemical and pharmaceutical technology aimed at inhibiting the phosphorylation of transcription factors STAT3 and ERK. The inhibitor primarily consists of mogrosides and/or their analogs, which have shown effectiveness in treating tumors by inhibiting cancer cell proliferation and promoting apoptosis. Another notable patent involves the use of statins in the treatment of ischemic diseases. This invention discloses statin compounds for local intraosseous application, particularly for treating peripheral ischemic diseases or cardio-cerebrovascular ischemic diseases.

Career Highlights

Can Liu has worked at prestigious institutions such as Beijing University of Agriculture and Peking University. His work at these universities has allowed him to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

Liu has collaborated with notable colleagues, including Lanqing Ma and Dequan Dou. These partnerships have further enhanced his research and development efforts in the pharmaceutical sector.

Conclusion

Can Liu's innovative work in chemical and pharmaceutical technology has led to significant advancements in the treatment of various diseases. His contributions continue to impact the medical field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…